Endogenous Promoters Drive Tumor-directed Payload Delivery from CAR T Cells

Major Finding: A CRISPR knock-in approach can drive CAR T-cell cytokine delivery in a tumor-localized manner.Concept: Delivery of IL12 or IL2 from the promoters of NR4A2 or RGS16 specifically targets the tumor site.Impact: The engineered CAR T cells demonstrate enhanced antitumor effects with a superior safety profile.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-rw2025-069
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endogenous Promoters Drive Tumor-directed Payload Delivery from CAR T Cells

Cancer Discovery
CAR-T cell therapy research
article

Endogenous Promoters Drive Tumor-directed Payload Delivery from CAR T Cells

article en

Abstract

Major Finding: A CRISPR knock-in approach can drive CAR T-cell cytokine delivery in a tumor-localized manner.Concept: Delivery of IL12 or IL2 from the promoters of NR4A2 or RGS16 specifically targets the tumor site.Impact: The engineered CAR T cells demonstrate enhanced antitumor effects with a superior safety profile.

Cancer Discovery
Openalex Percentile: Top 74%
CAR-T cell therapy research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Endogenous Promoters Drive Tumor-directed Payload Delivery from CAR T Cells · Cancer Discovery (2025) | TGRS Research Map | TGRS